| Year |
Citation |
Score |
| 2022 |
Van Trimpont M, Schalk AM, De Visser Y, Nguyen HA, Reunes L, Vandemeulebroecke K, Peeters E, Su Y, Lee H, Lorenzi PL, Chan WK, Mondelaers V, De Moerloose B, Lammens T, Goossens S, et al. stabilization of a less toxic asparaginase variant leads to a durable anti-tumor response in acute leukemia. Haematologica. PMID 35979719 DOI: 10.3324/haematol.2022.281390 |
0.312 |
|
| 2022 |
Grima-Reyes M, Vandenberghe A, Nemazanyy I, Meola P, Paul R, Reverso-Meinietti J, Martinez-Turtos A, Nottet N, Chan WK, Lorenzi PL, Marchetti S, Ricci JE, Chiche J. Tumoral microenvironment prevents de novo asparagine biosynthesis in B cell lymphoma, regardless of ASNS expression. Science Advances. 8: eabn6491. PMID 35857457 DOI: 10.1126/sciadv.abn6491 |
0.302 |
|
| 2020 |
Becker LM, O'Connell JT, Vo AP, Cain MP, Tampe D, Bizarro L, Sugimoto H, McGow AK, Asara JM, Lovisa S, McAndrews KM, Zielinski R, Lorenzi PL, Zeisberg M, Raza S, et al. Epigenetic Reprogramming of Cancer-Associated Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast Cancer. Cell Reports. 31: 107701. PMID 32492417 DOI: 10.1016/J.Celrep.2020.107701 |
0.335 |
|
| 2020 |
Lubkowski J, Vanegas JM, Chan WK, Lorenzi PL, Weinstein JN, Sukharev S, Fushman D, Rempe S, Anishkin A, Wlodawer A. The mechanism of catalysis by L-asparaginase. Biochemistry. PMID 32364696 DOI: 10.1021/Acs.Biochem.0C00116 |
0.327 |
|
| 2020 |
Petchampai N, Isoe J, Horvath TD, Dagan S, Tan L, Lorenzi PL, Hawke DH, Scaraffia PY. Mass spectrometry-based stable-isotope tracing uncovers metabolic alterations in pyruvate kinase-deficient Aedes aegypti mosquitoes. Insect Biochemistry and Molecular Biology. 103366. PMID 32276114 DOI: 10.1016/J.Ibmb.2020.103366 |
0.359 |
|
| 2019 |
Qian X, Li X, Shi Z, Xia Y, Cai Q, Xu D, Tan L, Du L, Zheng Y, Zhao D, Zhang C, Lorenzi PL, You Y, Jiang BH, Jiang T, et al. PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1. Molecular Cell. PMID 31492635 DOI: 10.1016/J.Molcel.2019.08.006 |
0.337 |
|
| 2019 |
Tabe Y, Lorenzi PL, Konopleva M. Amino Acid Metabolism in Hematologic Malignancies and the Era of Targeted Therapy. Blood. PMID 31416801 DOI: 10.1182/Blood.2019001034 |
0.42 |
|
| 2019 |
Chan WK, Horvath TD, Tan L, Link T, Harutyunyan KG, Pontikos MA, Anishkin A, Du D, Martin LA, Yin E, Rempe SB, Sukharev S, Konopleva M, Weinstein JN, Lorenzi PL. Glutaminase activity of L-asparaginase contributes to durable preclinical activity against acute lymphoblastic leukemia. Molecular Cancer Therapeutics. PMID 31209181 DOI: 10.1158/1535-7163.Mct-18-1329 |
0.391 |
|
| 2019 |
Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, ... ... Lorenzi PL, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Science Translational Medicine. 11. PMID 31068440 DOI: 10.1126/Scitranslmed.Aau1167 |
0.379 |
|
| 2019 |
Piya S, Mu H, Bhattacharya S, Lorenzi PL, Davis RE, McQueen T, Ruvolo V, Baran N, Wang Z, Qian Y, Crews CM, Konopleava M, Ishizawa J, You MJ, Kantarjian H, et al. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. The Journal of Clinical Investigation. 130. PMID 30829648 DOI: 10.1172/Jci120654 |
0.321 |
|
| 2019 |
Horvath TD, Chan WK, Pontikos MA, Martin LA, Du D, Tan L, Konopleva M, Weinstein JN, Lorenzi PL. Assessment of l-Asparaginase Pharmacodynamics in Mouse Models of Cancer. Metabolites. 9. PMID 30634463 DOI: 10.3390/Metabo9010010 |
0.338 |
|
| 2019 |
Sun Y, Bandi M, Lofton T, Smith M, Bristow CA, Carugo A, Rogers N, Leonard P, Chang Q, Mullinax R, Han J, Shi X, Seth S, Meyers BA, Miller M, ... ... Lorenzi PL, et al. Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation. Cell Reports. 26: 469-482.e5. PMID 30625329 DOI: 10.1016/J.Celrep.2018.12.043 |
0.36 |
|
| 2019 |
Baran N, Lodi A, Sweeney SR, Kuruvilla VM, Cavazos A, Herranz D, Skwarska A, Warmoes M, Davis E, Harutyunyan K, Feng N, Gay JP, Kaminski M, Konoplev S, Jabbour E, ... ... Lorenzi P, et al. Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism Blood. 134: 806-806. DOI: 10.1182/Blood-2019-128930 |
0.339 |
|
| 2019 |
Zeng Z, Baran N, Konoplev S, Cavazos A, Zhang Q, Kuruvilla VM, Lorenzi P, Kantarjian HM, Andreeff M, DiNardo CD, Murtie J, Ulanet D, Konopleva MY. Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and in Vivo Blood. 134: 3911-3911. DOI: 10.1182/Blood-2019-125469 |
0.339 |
|
| 2019 |
Carter BZ, Mak PY, Warmoes M, Tao W, Lorenzi P, Ruvolo V, Tan L, Cidado J, Drew L, Andreeff M. Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML Blood. 134: 3727-3727. DOI: 10.1182/Blood-2019-124453 |
0.396 |
|
| 2019 |
Chen L, Diao L, Yi X, Rodriguez BL, Li Y, Villalobos P, Cascone T, Liu X, Tan L, Lorenzi P, Fradette J, Peng D, Skoulidis F, Fan Y, Rodriguez-Canales J, et al. Abstract A059: Tackling the tumor microenvironment with CD38 blockade to enhance cancer immunotherapy Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A059 |
0.318 |
|
| 2018 |
Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette J, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discovery. PMID 30012853 DOI: 10.1158/2159-8290.Cd-17-1033 |
0.314 |
|
| 2018 |
Sen N, Cross AM, Lorenzi PL, Khan J, Gryder BE, Kim S, Caplen NJ. EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis. Molecular Carcinogenesis. PMID 29873416 DOI: 10.1002/Mc.22849 |
0.395 |
|
| 2018 |
Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D, Ge Z, Li J, Thomas GV, Birsoy K, Liu L, et al. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Reports. 23: 255-269.e4. PMID 29617665 DOI: 10.1016/J.Celrep.2018.03.077 |
0.358 |
|
| 2018 |
El-Hariry I, Aguera K, Hoke F, Swart K, Hamm A, Kay R, Lorenzi P. Pharmacodynamic characterization of eryaspase (L-asparaginase encapsulated in red blood cells) in combination with chemotherapy in a phase 2/3 trial in patients with relapsed acute lymphoblastic leukemia (NCT01518517). Journal of Clinical Oncology. 36: 7049-7049. DOI: 10.1200/Jco.2018.36.15_Suppl.7049 |
0.333 |
|
| 2018 |
Chan WK, Tan L, Harutyunyan K, Du D, Martin L, Yin E, Konopleva MY, Weinstein J, Lorenzi PL. The Glutaminase Activity of L-Asparaginase Mediates Suppression of Asns Upregulation Blood. 132: 3959-3959. DOI: 10.1182/Blood-2018-99-117818 |
0.486 |
|
| 2018 |
Baran N, Lodi A, Sweeney SR, Renu P, Kuruvilla VM, Cavazos A, Herranz D, Skwarska A, Warmoes M, Davis RE, Harutyunyan K, Feng N, Gay JP, Konoplev SN, Kaminski M, ... ... Lorenzi PL, et al. Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition Blood. 132: 4020-4020. DOI: 10.1182/Blood-2018-99-117310 |
0.362 |
|
| 2018 |
Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi PL, Mak D, Ruvolo V, Wang X, Ma H, Mu H, Cidado J, Drew L, Andreeff M. Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions Blood. 132: 768-768. DOI: 10.1182/Blood-2018-99-113491 |
0.371 |
|
| 2018 |
Konopleva MY, Lorenzi PL, Ghotbaldini S, Tabe Y, Cai T, Tiziani S. Contribution of Amino Acid Metabolism to Hematologic Malignancies Blood. 132: SCI-10-SCI-10. DOI: 10.1182/Blood-2018-99-109469 |
0.47 |
|
| 2017 |
Qian X, Li X, Tan L, Lee JH, Xia Y, Cai Q, Zheng Y, Wang H, Lorenzi PL, Lu Z. Conversion of PRPS hexamer to monomer by AMPK-mediated phosphorylation inhibits nucleotide synthesis in response to energy stress. Cancer Discovery. PMID 29074724 DOI: 10.1158/2159-8290.Cd-17-0712 |
0.317 |
|
| 2017 |
Horvath TD, Dagan S, Lorenzi PL, Hawke DH, Scaraffia PY. Positional stable isotope tracer analysis reveals carbon routes during ammonia metabolism of Aedes aegypti mosquitoes. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 28970248 DOI: 10.1096/Fj.201700657R |
0.351 |
|
| 2017 |
Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, Vellano CP, Ju Z, Gagea M, Liu S, Mitra S, Dennison JB, Lorenzi PL, Cardnell R, Diao L, et al. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Science Advances. 3: e1600957. PMID 28439535 DOI: 10.1126/Sciadv.1600957 |
0.338 |
|
| 2017 |
Aguera K, Senechal K, Lorenzi P, Scheer A, Horand F, Bourgeaux V. Abstract 2134: Use of methionine gamma-lyase-loaded erythrocytes to induce effective methionine depletion in cancer therapy Cancer Research. 77: 2134-2134. DOI: 10.1158/1538-7445.Am2017-2134 |
0.317 |
|
| 2017 |
Cai T, Lorenzi P, Rakheja D, Pontikos M, Lodi A, Han L, Zhang Q, Ma H, Rahmani M, Bhagat T, Horvath T, DiNardo C, Grant S, Tiziani S, Verma A, et al. GLS Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth when Combined with 5-Azacitidine Clinical Lymphoma Myeloma and Leukemia. 17: S285-S286. DOI: 10.1016/J.Clml.2017.07.070 |
0.347 |
|
| 2016 |
Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, ... ... Lorenzi PL, et al. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Science Signaling. 9: ra17. PMID 26884599 DOI: 10.1126/Scisignal.Aac4380 |
0.322 |
|
| 2016 |
Piya S, Bhattacharya S, Mu H, Lorenzi PL, McQueen T, Davis ER, Ruvolo V, Baran N, Qian Y, Crews C, Kantarjian HM, Andreeff M, Borthakur G. BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects Blood. 128: 748-748. DOI: 10.1182/Blood.V128.22.748.748 |
0.422 |
|
| 2016 |
Cai T, Lorenzi PL, Rakheja D, Pontikos MA, Lodi A, Han L, Zhang Q, Ma H, Rahmani M, Bhagat TD, Horvath TD, DiNardo CD, Grant S, Tiziani S, Verma A, et al. Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine Blood. 128: 4064-4064. DOI: 10.1182/Blood.V128.22.4064.4064 |
0.445 |
|
| 2016 |
Lorenzi PL, Horvath TD, Martin LA, Chan WK, Du D, Hawke DH, Weinstein JN, Swart KJ, El-Hariry I. Red Blood Cell-Encapsulation of L-Asparaginase Favorably Modulates Target Selectivity and Pharmacodynamics Blood. 128: 1266-1266. DOI: 10.1182/Blood.V128.22.1266.1266 |
0.431 |
|
| 2016 |
Aguera K, Senechal K, Bes J, Chevrier A, Gallix F, Guicher C, Lorenzi P, Bourgeaux V, Berlier W, Horand F, Godfrin Y. Abstract 4812: Arginine deiminase loaded in erythrocytes: a promising formulation for L-arginine deprivation therapy in cancers Cancer Research. 76: 4812-4812. DOI: 10.1158/1538-7445.Am2016-4812 |
0.404 |
|
| 2016 |
Cai T, Lorenzi PL, Rakheja D, Pontikos M, Han L, Zhang Q, Ma H, Horvath TD, Verma AK, Konopleva M. Abstract 1004: GLS inhibitor CB-839 modulates cellular metabolism in AML and potently suppresses AML cell growth when combined with 5-azacitidine Cancer Research. 76: 1004-1004. DOI: 10.1158/1538-7445.Am2016-1004 |
0.443 |
|
| 2016 |
Piya S, Lorenzi P, McQueen T, Davis E, Qian Y, Andreeff M, Borthakur G. ARV-825, a BRD4 Inhibitor, Leads to Sustained Degradation of BRD4 with Broad Activity Against Acute Myeloid Leukemia and Overcomes Stroma Mediated Resistance by Modulating Chemokine Receptor, Cell Adhesion and Metabolic Targets Clinical Lymphoma Myeloma and Leukemia. 16: S36-S37. DOI: 10.1016/J.Clml.2016.07.051 |
0.349 |
|
| 2015 |
Anishkin A, Vanegas JM, Rogers DM, Lorenzi PL, Chan WK, Purwaha P, Weinstein JN, Sukharev S, Rempe SB. Catalytic Role of the Substrate Defines Specificity of Therapeutic l-Asparaginase. Journal of Molecular Biology. 427: 2867-85. PMID 26142822 DOI: 10.1016/J.Jmb.2015.06.017 |
0.377 |
|
| 2014 |
Purwaha P, Lorenzi PL, Silva LP, Hawke DH, Weinstein JN. Targeted metabolomic analysis of amino acid response to L-asparaginase in adherent cells. Metabolomics : Official Journal of the Metabolomic Society. 10: 909-919. PMID 25177232 DOI: 10.1007/S11306-014-0634-1 |
0.476 |
|
| 2014 |
Lorenzi PL, Claerhout S, Mills GB, Weinstein JN. A curated census of autophagy-modulating proteins and small molecules: candidate targets for cancer therapy. Autophagy. 10: 1316-26. PMID 24906121 DOI: 10.4161/Auto.28773 |
0.327 |
|
| 2014 |
Chan WK, Lorenzi PL, Anishkin A, Purwaha P, Rogers DM, Sukharev S, Rempe SB, Weinstein JN. The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells. Blood. 123: 3596-606. PMID 24659632 DOI: 10.1182/Blood-2013-10-535112 |
0.417 |
|
| 2014 |
Weinstein JN, Peng B, Reinhold WC, Pommier Y, Lorenzi PL. Abstract 3788: Drug mechanisms of action: Triangulating with cultured cancer cells Cancer Research. 74: 3788-3788. DOI: 10.1158/1538-7445.Am2014-3788 |
0.365 |
|
| 2013 |
Weinstein JN, Lorenzi PL. Cancer: Discrepancies in drug sensitivity. Nature. 504: 381-3. PMID 24284624 DOI: 10.1038/Nature12839 |
0.316 |
|
| 2012 |
Dufour E, Gay F, Aguera K, Scoazec JY, Horand F, Lorenzi PL, Godfrin Y. Pancreatic tumor sensitivity to plasma L-asparagine starvation. Pancreas. 41: 940-8. PMID 22513289 DOI: 10.1097/Mpa.0B013E318247D903 |
0.352 |
|
| 2012 |
Lorenzi PL, Heathcock LE, Aldape K, Weinstein JN. Abstract 887: Development of a robust nanoimmunoassay and immunohistochemical assay for asparagine synthetase Cancer Research. 72: 887-887. DOI: 10.1158/1538-7445.Am2012-887 |
0.384 |
|
| 2011 |
Claerhout S, Lorenzi PL, Weinstein JN, Mills GB. MODULATION OF AUTOPHAGY AND ITS POTENTIAL FOR CANCER THERAPY. Drugs of the Future. 36. PMID 25419038 DOI: 10.1358/Dof.2011.036.12.1711892 |
0.319 |
|
| 2011 |
Dufour E, Aguera K, Lorenzi P, Scoazec J, Horand F, Godfrin Y. Abstract 4137: L-asparagine synthetase in solid tumors: Screening and implication in pancreatic cancer Cancer Research. 71: 4137-4137. DOI: 10.1158/1538-7445.Am2011-4137 |
0.41 |
|
| 2010 |
Liu H, D'Andrade P, Fulmer-Smentek S, Lorenzi P, Kohn KW, Weinstein JN, Pommier Y, Reinhold WC. mRNA and microRNA Expression Profiles of the NCI-60 Integrated with Drug Activities Molecular Cancer Therapeutics. 9: 1080-1091. PMID 20442302 DOI: 10.1158/1535-7163.Mct-09-0965 |
0.319 |
|
| 2010 |
Dufour E, Aguera K, Lorenzi P, Gay F, Horand F, Godfrin Y. Efficacy of L-asparaginase loaded red blood cells combined with gemcitabine on pancreatic cancer. Journal of Clinical Oncology. 28: e14666-e14666. DOI: 10.1200/Jco.2010.28.15_Suppl.E14666 |
0.4 |
|
| 2010 |
Lorenzi PL, Llamas J, Caplen NJ, Weinstein JN. Abstract 1683: ATF4 down-regulation potentiates L-asparaginase activity in ovarian cancer cell lines Cancer Research. 70: 1683-1683. DOI: 10.1158/1538-7445.Am10-1683 |
0.374 |
|
| 2009 |
Jobson AG, Lountos GT, Lorenzi PL, Llamas J, Connelly J, Cerna D, Tropea JE, Onda A, Zoppoli G, Kondapaka S, Zhang G, Caplen NJ, Cardellina JH, Yoo SS, Monks A, et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. The Journal of Pharmacology and Experimental Therapeutics. 331: 816-26. PMID 19741151 DOI: 10.1124/Jpet.109.154997 |
0.385 |
|
| 2009 |
Lorenzi PL, Weinstein JN. Asparagine synthetase: a new potential biomarker in ovarian cancer. Drug News & Perspectives. 22: 61-4. PMID 19209300 DOI: 10.1358/Dnp.2009.22.11303820 |
0.381 |
|
| 2009 |
Jobson A, Lountos GT, Lorenzi P, Connelly J, Tropea JE, Zoppoli G, Kondapaka S, Zhang G, Caplen NJ, Cardellina JH, Yoo SS, Monks A, Self C, Waugh DS, Shoemaker RH, et al. Abstract A120: Cellular inhibition of Chk2 kinase and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A120 |
0.369 |
|
| 2008 |
Lorenzi PL, Llamas J, Gunsior M, Ozbun L, Reinhold WC, Varma S, Ji H, Kim H, Hutchinson AA, Kohn EC, Goldsmith PK, Birrer MJ, Weinstein JN. Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Molecular Cancer Therapeutics. 7: 3123-8. PMID 18852115 DOI: 10.1158/1535-7163.Mct-08-0589 |
0.378 |
|
| 2007 |
Miao ZH, Player A, Shankavaram U, Wang YH, Zimonjic DB, Lorenzi PL, Liao ZY, Liu H, Shimura T, Zhang HL, Meng LH, Zhang YW, Kawasaki ES, Popescu NC, Aladjem MI, et al. Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Research. 67: 8752-61. PMID 17875716 DOI: 10.1158/0008-5472.Can-06-4554 |
0.363 |
|
| 2007 |
Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z, Liu CG, Reinhold W, Lorenzi PL, Kaldjian EP, Croce CM, Weinstein JN, Sadee W. MicroRNA expression profiles for the NCI-60 cancer cell panel. Molecular Cancer Therapeutics. 6: 1483-91. PMID 17483436 DOI: 10.1158/1535-7163.Mct-07-0009 |
0.314 |
|
| 2006 |
Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, Scherf U, Eichler GS, Martin SE, Chin K, Gray JW, Kohn EC, Horak ID, Von Hoff DD, Raffeld M, et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Molecular Cancer Therapeutics. 5: 2613-23. PMID 17088436 DOI: 10.1158/1535-7163.Mct-06-0447 |
0.422 |
|
| 2006 |
Lorenzi PL, Landowski CP, Brancale A, Song X, Townsend LB, Drach JC, Amidon GL. N-methylpurine DNA glycosylase and 8-oxoguanine dna glycosylase metabolize the antiviral nucleoside 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 1070-7. PMID 16565170 DOI: 10.1124/Dmd.105.009209 |
0.693 |
|
| 2006 |
Landowski CP, Lorenzi PL, Song X, Amidon GL. Nucleoside ester prodrug substrate specificity of liver carboxylesterase. The Journal of Pharmacology and Experimental Therapeutics. 316: 572-80. PMID 16223870 DOI: 10.1124/Jpet.105.092726 |
0.699 |
|
| 2005 |
Landowski CP, Song X, Lorenzi PL, Hilfinger JM, Amidon GL. Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharmaceutical Research. 22: 1510-8. PMID 16132363 DOI: 10.1007/S11095-005-6156-9 |
0.733 |
|
| 2005 |
Lorenzi PL, Landowski CP, Song X, Borysko KZ, Breitenbach JM, Kim JS, Hilfinger JM, Townsend LB, Drach JC, Amidon GL. Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo. The Journal of Pharmacology and Experimental Therapeutics. 314: 883-90. PMID 15901797 DOI: 10.1124/Jpet.104.082412 |
0.735 |
|
| 2005 |
Song X, Lorenzi PL, Landowski CP, Vig BS, Hilfinger JM, Amidon GL. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Molecular Pharmaceutics. 2: 157-67. PMID 15804190 DOI: 10.1021/Mp049888E |
0.727 |
|
| 2005 |
Song X, Vig BS, Lorenzi PL, Drach JC, Townsend LB, Amidon GL. Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter. Journal of Medicinal Chemistry. 48: 1274-7. PMID 15715497 DOI: 10.1021/Jm049450I |
0.56 |
|
| Show low-probability matches. |